SG11201507221VA - Crystalline form of a substituted thiazolylacetic acid triethylamine salt - Google Patents

Crystalline form of a substituted thiazolylacetic acid triethylamine salt

Info

Publication number
SG11201507221VA
SG11201507221VA SG11201507221VA SG11201507221VA SG11201507221VA SG 11201507221V A SG11201507221V A SG 11201507221VA SG 11201507221V A SG11201507221V A SG 11201507221VA SG 11201507221V A SG11201507221V A SG 11201507221VA SG 11201507221V A SG11201507221V A SG 11201507221VA
Authority
SG
Singapore
Prior art keywords
crystalline form
triethylamine salt
acid triethylamine
substituted
thiazolylacetic acid
Prior art date
Application number
SG11201507221VA
Inventor
Weijiang Zhang
Michael R Tracey
Junning Lee
Original Assignee
Theravance Biopharma Antibiotics Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics Ip Llc filed Critical Theravance Biopharma Antibiotics Ip Llc
Publication of SG11201507221VA publication Critical patent/SG11201507221VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • C07D277/593Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
SG11201507221VA 2013-03-13 2014-03-06 Crystalline form of a substituted thiazolylacetic acid triethylamine salt SG11201507221VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779091P 2013-03-13 2013-03-13
PCT/US2014/021080 WO2014164187A1 (en) 2013-03-13 2014-03-06 Crystalline form of a substituted thiazolylacetic acid triethylamine salt

Publications (1)

Publication Number Publication Date
SG11201507221VA true SG11201507221VA (en) 2015-10-29

Family

ID=50382685

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507221VA SG11201507221VA (en) 2013-03-13 2014-03-06 Crystalline form of a substituted thiazolylacetic acid triethylamine salt

Country Status (20)

Country Link
US (1) US9139542B2 (en)
EP (1) EP2970164B1 (en)
JP (2) JP6404309B2 (en)
KR (1) KR20150126368A (en)
CN (1) CN105121417B (en)
AU (1) AU2014249611B2 (en)
BR (1) BR112015022600A2 (en)
CA (1) CA2902724A1 (en)
EA (1) EA027911B1 (en)
ES (1) ES2634019T3 (en)
GE (1) GEP201706779B (en)
HK (1) HK1214596A1 (en)
IL (1) IL240600A0 (en)
MD (1) MD4719C1 (en)
MX (1) MX351963B (en)
PH (1) PH12015502067A1 (en)
SG (1) SG11201507221VA (en)
TW (1) TWI627165B (en)
UA (1) UA115087C2 (en)
WO (1) WO2014164187A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220213051A1 (en) * 2019-05-31 2022-07-07 Hyundai Pharm Co., Ltd. Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284631A (en) 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
US4372952A (en) 1978-07-31 1983-02-08 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
DE2945248A1 (en) 1978-11-13 1980-05-22 Fujisawa Pharmaceutical Co CEPHEM COMPOUNDS, METHOD FOR THEIR PRODUCTION AND ANTIBACTERIAL PHARMACEUTICAL AGENTS CONTAINING THE SAME
DE3177090D1 (en) * 1980-12-31 1989-09-28 Fujisawa Pharmaceutical Co 7-acylaminocephalosporanic acid derivatives and processes for the preparation thereof
JP2519054B2 (en) 1986-06-09 1996-07-31 武田薬品工業株式会社 New cephem compound
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
JPH04221388A (en) * 1990-12-20 1992-08-11 Asahi Chem Ind Co Ltd Cephalosporin compound and production thereof
TWI335332B (en) 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
ITMI20012363A1 (en) 2001-11-09 2003-05-09 Antibioticos Spa METHOD FOR THE SYNTHESIS OF SIDE CHAINS OF CEPHALOSPORINE
EP1507796B1 (en) 2002-05-24 2012-05-02 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
GB0416379D0 (en) 2004-07-22 2004-08-25 Sandoz Ag Organic compounds
TW200637559A (en) 2005-03-29 2006-11-01 Shionogi & Co 3-propenylcefem derivative

Also Published As

Publication number Publication date
JP2016512257A (en) 2016-04-25
CN105121417B (en) 2017-11-17
GEP201706779B (en) 2017-11-27
AU2014249611B2 (en) 2017-12-21
EP2970164B1 (en) 2017-05-03
IL240600A0 (en) 2015-09-24
BR112015022600A2 (en) 2017-07-18
CA2902724A1 (en) 2014-10-09
EA201591708A1 (en) 2016-01-29
US9139542B2 (en) 2015-09-22
EA027911B1 (en) 2017-09-29
AU2014249611A1 (en) 2015-09-17
MD20150099A2 (en) 2016-02-29
MD4719B1 (en) 2020-10-31
JP6404309B2 (en) 2018-10-10
TW201444810A (en) 2014-12-01
JP2018197256A (en) 2018-12-13
UA115087C2 (en) 2017-09-11
KR20150126368A (en) 2015-11-11
WO2014164187A1 (en) 2014-10-09
MX2015012146A (en) 2015-11-25
TWI627165B (en) 2018-06-21
ES2634019T3 (en) 2017-09-26
PH12015502067B1 (en) 2016-01-25
EP2970164A1 (en) 2016-01-20
HK1214596A1 (en) 2016-07-29
CN105121417A (en) 2015-12-02
PH12015502067A1 (en) 2016-01-25
MD4719C1 (en) 2021-05-31
US20140275554A1 (en) 2014-09-18
MX351963B (en) 2017-11-06

Similar Documents

Publication Publication Date Title
HK1224226A1 (en) Nicotine salt with m eta-salicylic acid
IL245865B (en) Crystalline form i of ibrutinib
HK1222334A1 (en) Crystalline forms of antiviral sofosbuvir analogues
EP2970081A4 (en) Salts of treprostinil
RS61192B1 (en) Crystalline form of a mdm2 inhibitor
EP2863918A4 (en) Salt crystals
RU2016118399A3 (en) 4-aminomethylbenzoic acid derivative
HK1217331A1 (en) Crystalline forms of [1-cyano-5-(4-chlorophenoxy)-4-hydroxy- isoquinoline-3-carbonyl]-amino-acetic acid [1--5-(4-)-4---3-]--
EP2975022A4 (en) Novel hydroxamic acid derivative or salt thereof
GB2519787B (en) Process for the preparation of herbicidal carboxylic acid salts
HK1220458A1 (en) Polymorphs and salts of a compound
HK1220187A1 (en) A crystalline form of an anxiolytic compound
HK1200454A1 (en) Crystalline form of a succinate salt
EP3021849A4 (en) Novel crystalline forms of pemetrexed tromethamine salts
HK1214596A1 (en) Crystalline form of a substituted thiazolylacetic acid triethylamine salt
EP2977459A4 (en) Method for producing 5-aminolevulinic acid or salt thereof
EP2970188A4 (en) Novel crystalline forms
GB201300903D0 (en) Crystalline Form
SG11201509307VA (en) Crystalline forms of zinc trisodium pentetic acid
GB201322785D0 (en) Manufacture of lactic acid
AU2013903615A0 (en) Process for preparation of herbicidal salts
TH1401007860A (en) Dimethyl-benzoic acid compound